Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 6,683 matching trials from the live ClinicalTrials.gov search.

Filters: Stanford, California Clear all

Conditions: Respiration
Interventions: Non-Contact Respiratory Rate Monitor; Device
Lead sponsor: Kai Medical, Inc.; Industry
Eligibility: 29 Days and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Cystic Fibrosis
Interventions: N91115; Drug
Lead sponsor: Nivalis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 19
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 15 more

Conditions: Macular Telangiectasia Type 2 (MacTel)
Interventions: NT-501/revakinagene taroretcel-lwey; Combination Product
Lead sponsor: Neurotech Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 23
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 19 more

Conditions: Venous Leg Ulcer
Interventions: EscharEx (5% EX-02 formulation), Gel Vehicle, Non-surgical standard of care (NSSOC); Drug
Lead sponsor: MediWound Ltd; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 21
States / cities: Carlsbad, California • Fresno, California • Los Angeles, California + 17 more

Conditions: Primary IgA Nephropathy
Interventions: Nefecon, Placebo oral capsule; Drug
Lead sponsor: Calliditas Therapeutics AB; Industry
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 34
States / cities: Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 28 more

Conditions: Immunization; Infection, Transplantation Infection, Influenza
Interventions: Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 17 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Stanford, California • Atlanta, Georgia • Chicago, Illinois + 8 more

Conditions: Organ Transplantation
Interventions: everolimus (RAD); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 68
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 51 more

Conditions: Hepatitis C Virus
Interventions: Pegylated-Interferon-lambda, Ribavirin, Daclatasvir; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Palo Alto, California • Chicago, Illinois • Philadelphia, Pennsylvania + 1 more

Conditions: Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
Interventions: Cisplatin, No treatment; Drug · Other
Lead sponsor: GOG Foundation; Network
Eligibility: 18 Years and older · Female only
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 59
States / cities: Duarte, California • La Jolla, California • Newport Beach, California + 43 more

Conditions: Muscular Atrophy, Spinal
Interventions: Nusinersen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 2 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Sacramento, California • Aurora, Colorado • Chicago, Illinois + 4 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
Interventions: Pembrolizumab, Patient Observation, Biopsy, Biospecimen Collection, Questionnaire Administration, Quality-of-Life Assessment; Biological · Other · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 828
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 600 more

Conditions: Cardiac Allograft Vasculopathy
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Type 1 Diabetes Mellitus
Interventions: t:slim X2 with Control-IQ Technology & Dexcom G6 CGM, Sensor-augmented pump (SAP); Device
Lead sponsor: University of Virginia; Other
Eligibility: 14 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Santa Barbara, California • Stanford, California • Aurora, Colorado + 4 more

Conditions: Ductus Arteriosus, Patent
Interventions: Percutaneous Patent Ductus Arteriosus Closure (PPC), Responsive Management Intervention, Echocardiogram, cardiac; Device · Combination Product · Diagnostic Test
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 7 Days to 32 Days
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: Myopia, Astigmatism
Interventions: LASIK with the iFS femtosecond laser; Procedure
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: Breast Reconstruction
Interventions: ARTIA Reconstructive Tissue Matrix; Device
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 23
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 20 more

Conditions: Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
Interventions: Edoxaban, Standard of Care; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 1 Day to 17 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 22
States / cities: Tucson, Arizona • Los Angeles, California • Stanford, California + 16 more

Conditions: Hip Osteoarthritis, Knee Osteoarthritis
Interventions: Shared Decision Making Intervention; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Redwood City, California • San Francisco, California

Conditions: Carcinoma, Renal Cell
Interventions: foretinib (formerly GSK1363089 or XL880); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 12
States / cities: Greenbrae, California • San Francisco, California • Stanford, California + 9 more

Conditions: Language Development
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: Up to 18 Months
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: HIV, HIV Infections
Interventions: Stribild, Atripla, Stribild Placebo, Atripla Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 97
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 63 more

Conditions: Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Interventions: Radiation Therapy, Carboplatin, Cisplatin, Crizotinib, Erlotinib, Etoposide, Paclitaxel; Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 174
States / cities: Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 137 more

Conditions: Lifestyle, Healthy, Sleepiness, Alertness, Shift-Work Related Sleep Disturbance, Work Related Stress, Self Efficacy, Self-Compassion
Interventions: Personalized lifestyle coaching and educational handout, Handout; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 21 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Acute Lymphoblastic Leukemia
Interventions: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 17,463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 214
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more

Search by objective public record fields.

Substantial Equivalence Study for Kai Medical Non-Contact Respiratory Rate Monitor

Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation

Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation

Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation

The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas

Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

An Outcomes Study Comparing the Intralase FS 60 to the Intralase iFS When Performing LASIK Surgery for Nearsightedness

Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

Shared Decision Making in Patients With Osteoarthritis of the Hip and Knee

A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

Language Development in Preterm Children

Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Lifestyle Coaching for Fatigue Mitigation in Emergency Medicine Residents

Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia